2023 AbbVie Innovation Midwest Award

AbbVie Ventures is excited to launch the 2023 AbbVie Innovation Midwest (AIM) awards, our signature event to catalyze the formation of new biotech companies and support a thriving biopharma ecosystem in our backyard. To propel groundbreaking therapeutic innovations, AbbVie Ventures again offers two awards, including an equity investment of up to two million dollars per award and support from AbbVie R&D, to winners developing novel, transformative therapies.

Together, we break through

AbbVie Ventures is focused on novel science and technology with the potential to generate transformational therapies in areas that align with our strategic areas of interest.

Application core requirements:

The AIM award is limited to biotechs (and biotechs-to-be) working on next-generation biologics, small molecules, genetic medicine technologies (including RNA and DNA-based therapies, in situ cellular programming, and gene therapy delivery), and platform technologies for target identification and validation in the following areas: 

  • Immunology
  • Oncology
  • Neuroscience
  • Eye Care
  • Genetic Medicine Technologies (RNA and DNA)

* Exclusions: Diagnostics, Devices, Research Tools, Nutrition, and Healthcare Services/IT

Additional requirements:
  • Companies must have the principal place of business in the Midwest, or be willing to establish a presence in the Midwest
  • Companies must not yet have partnered substantive parts of the pipeline or platform with another large biopharmaceutical company 
    • Current or prior recipients of similar early-innovation awards sponsored by other pharmaceutical companies or lab spaces are eligible to apply
  • Companies must meet the following AbbVie funding award criteria:
    • Total equity funding raised to date must be less than USD 5 million before receiving the AIM award
    • Companies must not have sales revenue
    • Companies must be in the life sciences and have an impact on human health or therapeutic drug development

How to apply

Please send your application to [email protected] by 11:59pm CT July 7, 2023. Applicants may only submit one entry each.